<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Champion Enterprises Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/champion-enterprises-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BMY) Bristol-Myers Squibb Beats Expectations on EPS &#8211; Misses on Sales</title>
		<link>http://www.stockbloghub.com/2010/11/07/bmy-bristol-myers-squibb-beats-expectations-on-eps-misses-on-sales/56688</link>
		<comments>http://www.stockbloghub.com/2010/11/07/bmy-bristol-myers-squibb-beats-expectations-on-eps-misses-on-sales/56688#comments</comments>
		<pubDate>Sun, 07 Nov 2010 20:29:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Enterprises Inc.]]></category>
		<category><![CDATA[CHB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56688</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) third quarter 2010 earnings (excluding special items) of $0.59 per share surpassed the Zacks Consensus Estimate by $0.06. The company had earned $0.47 per share in the year-ago quarter. On a reported basis (including special items), Bristol-Myers’ earnings in the reported quarter climbed 22% to $0.55 per share. Even though Bristol-Myers’ lead product Plavix and therapies indicated for HIV and hepatitis performed well in the quarter, the better than expected earnings were mainly driven by cost controls and lower taxes. Net sales in the reported quarter came in flat at $4.8 billion. Revenues were short of the Zacks Consensus revenue Estimate of $4.9 billion mainly because of lower sales of Abilify, approved for the treatment of schizophrenia and depression, cancer drug Erbitux and hypertension treatment Avapro. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/07/bmy-bristol-myers-squibb-beats-expectations-on-eps-misses-on-sales/56688/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EHTH) Is eHealth Getting Ahead of Itself?</title>
		<link>http://www.stockbloghub.com/2009/04/23/ehth-is-ehealth-getting-ahead-of-itself/5970</link>
		<comments>http://www.stockbloghub.com/2009/04/23/ehth-is-ehealth-getting-ahead-of-itself/5970#comments</comments>
		<pubDate>Thu, 23 Apr 2009 21:30:59 +0000</pubDate>
		<dc:creator>PeakStocks.com</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Insurance Brokers]]></category>
		<category><![CDATA[Champion Enterprises Inc.]]></category>
		<category><![CDATA[CHB]]></category>
		<category><![CDATA[eHealth]]></category>
		<category><![CDATA[EHTH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5970</guid>
		<description><![CDATA[It’s been a rather quiet quarter for eHealth, Inc. (NASDAQ: EHTH), the nation’s leading online source of health insurance for individuals, families and small businesses. With their upcoming earnings for Q1/2009 set to be released after the market closes on April 28th, we’ll be able to check in on one of the stalwarts of the PeakStocks.com portfolio and a company that is up 35% since I originally recommended purchase last October, and is beating the overall market by 50%. I previously wrote, after the company reported stellar Q4/08 and full year 2008 earnings, that eHealth was a beacon of light in an otherwise tumultuous market. The question is, with eHealth’s strength and stock price rise, are shares a little top heavy now? Are analyst’s expectations getting ahead of themselves? In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/23/ehth-is-ehealth-getting-ahead-of-itself/5970/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

